Q-linea AB (publ) researches, develops, manufactures, and sells instruments and consumables for infection diagnostics. More Details
Excellent balance sheet with limited growth.
Share Price & News
How has Q-linea's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: QLINEA's share price has been volatile over the past 3 months.
7 Day Return
SE Medical Equipment
1 Year Return
SE Medical Equipment
Return vs Industry: QLINEA exceeded the Swedish Medical Equipment industry which returned 24% over the past year.
Return vs Market: QLINEA exceeded the Swedish Market which returned 17.8% over the past year.
Price Volatility Vs. Market
How volatile is Q-linea's share price compared to the market and industry in the last 5 years?
Simply Wall St News
1 month ago | Simply Wall StHow Much Of Q-linea AB (publ) (STO:QLINEA) Do Insiders Own?
2 months ago | Simply Wall StHere's Why We're Not Too Worried About Q-linea's (STO:QLINEA) Cash Burn Situation
5 months ago | Simply Wall StShould Q-linea (STO:QLINEA) Be Disappointed With Their 19% Profit?
Is Q-linea undervalued compared to its fair value and its price relative to the market?
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate QLINEA's fair value to establish if it is undervalued.
Significantly Below Fair Value: Insufficient data to calculate QLINEA's fair value to establish if it is undervalued.
Price To Earnings Ratio
PE vs Industry: QLINEA is unprofitable, so we can't compare its PE Ratio to the SE Medical Equipment industry average.
PE vs Market: QLINEA is unprofitable, so we can't compare its PE Ratio to the Swedish market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate QLINEA's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: QLINEA is overvalued based on its PB Ratio (8.2x) compared to the SE Medical Equipment industry average (5.3x).
How is Q-linea forecast to perform in the next 1 to 3 years based on estimates from 2 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: QLINEA is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: QLINEA is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: QLINEA is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: QLINEA's revenue (64.2% per year) is forecast to grow faster than the Swedish market (3% per year).
High Growth Revenue: QLINEA's revenue (64.2% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: QLINEA is forecast to be unprofitable in 3 years.
How has Q-linea performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: QLINEA is currently unprofitable.
Growing Profit Margin: QLINEA is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: QLINEA is unprofitable, and losses have increased over the past 5 years at a rate of 32.6% per year.
Accelerating Growth: Unable to compare QLINEA's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: QLINEA is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (18.4%).
Return on Equity
High ROE: QLINEA has a negative Return on Equity (-43.49%), as it is currently unprofitable.
How is Q-linea's financial position?
Financial Position Analysis
Short Term Liabilities: QLINEA's short term assets (SEK396.2M) exceed its short term liabilities (SEK32.7M).
Long Term Liabilities: QLINEA's short term assets (SEK396.2M) exceed its long term liabilities (SEK171.0K).
Debt to Equity History and Analysis
Debt Level: QLINEA's debt to equity ratio (0.1%) is considered satisfactory.
Reducing Debt: Insufficient data to determine if QLINEA's debt to equity ratio has reduced over the past 5 years.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: QLINEA has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: QLINEA has sufficient cash runway for 2.1 years if free cash flow continues to reduce at historical rates of 35.2% each year.
What is Q-linea current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate QLINEA's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate QLINEA's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if QLINEA's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if QLINEA's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of QLINEA's dividend in 3 years as they are not forecast to pay a notable one for the Swedish market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Jonas Jarvius (49 yo)
Dr. Jonas Jarvius, Ph.D serves as the Chief Executive Officer and President of Q-linea AB. Dr. Jarvius served as Director at QuiaPEG Pharmaceuticals Holding AB (publ) since 2019 until 2020. Dr. Jarvius ser ...
CEO Compensation Analysis
Compensation vs Market: Jonas's total compensation ($USD475.90K) is about average for companies of similar size in the Swedish market ($USD491.17K).
Compensation vs Earnings: Jonas's compensation has increased whilst the company is unprofitable.
|CEO & President||12.75yrs||kr4.21m||1.34% |
|Chief Financial Officer||2.75yrs||no data||0.054% |
|Chief Operating Officer||3.75yrs||no data||0.0016% |
|Sales & Marketing Director||0.75yr||no data||0.0016% |
|Chief Medical Officer||1.25yrs||no data||no data|
|Chief Commercial Officer||1.08yrs||no data||0.017% |
|VP & Research Director||no data||no data||0.036% |
Experienced Management: QLINEA's management team is considered experienced (2 years average tenure).
|Independent Director||2.75yrs||kr155.00k||no data|
|Independent Director||2.75yrs||kr155.00k||0.022% |
|Independent Director||2.75yrs||kr185.00k||0.019% |
|Independent Director||2.75yrs||kr225.00k||0.011% |
|Independent Chairperson||2.75yrs||no data||no data|
|Director||0.42yr||no data||no data|
Experienced Board: QLINEA's board of directors are not considered experienced ( 2.8 years average tenure), which suggests a new board.
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 17.3%.
Q-linea AB (publ)'s company bio, employee growth, exchange listings and data sources
- Name: Q-linea AB (publ)
- Ticker: QLINEA
- Exchange: OM
- Founded: 2008
- Industry: Health Care Equipment
- Sector: Healthcare
- Market Cap: kr3.984b
- Shares outstanding: 27.01m
- Website: https://www.qlinea.com
Number of Employees
- Q-linea AB (publ)
- Dag Hammarskjölds väg 52 A
- Uppsala County
- 752 37
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|QLINEA||OM (OMX Nordic Exchange Stockholm)||Yes||Ordinary Shares||SE||SEK||Dec 2018|
|3F8||DB (Deutsche Boerse AG)||Yes||Ordinary Shares||DE||EUR||Dec 2018|
|QLINES||BATS-CHIXE (BATS 'Chi-X Europe')||Yes||Ordinary Shares||GB||SEK||Dec 2018|
Q-linea AB (publ) researches, develops, manufactures, and sells instruments and consumables for infection diagnostics. It offers inventive systems for in vitro diagnostics systems for infectious diseases. ...
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2020/10/18 22:23|
|End of Day Share Price||2020/10/16 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.